Comparative Renal Toxicopathology of Antisense Oligonucleotides

Nucleic Acid Therapeutics

Volumn 26, Issue 4, 2016, Pages 199-209

  Engelhardt, Jeffery A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMINOGLYCOSIDE; ANGIOTENSIN II; ANTISENSE OLIGONUCLEOTIDE; CYTOCHROME P450; MIXED FUNCTION OXIDASE; PHOSPHOLIPASE A; PHOSPHOLIPASE C; XENOBIOTIC AGENT;

ACUTE KIDNEY FAILURE; ANATOMICAL CONCEPTS; CELL METABOLISM; CELL ORGANELLE; CELL VACUOLE; GLOMERULONEPHRITIS; GLOMERULUS; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; HENLE LOOP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY BLOOD FLOW; KIDNEY COLLECTING TUBULE; KIDNEY CONCENTRATING CAPACITY; KIDNEY DISTAL TUBULE; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY PAPILLA; KIDNEY PAPILLA NECROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KIDNEY TUBULE NECROSIS; LIPIDOSIS; MACROMOLECULE; MESANGIUM; MESANGIUM CELL; MICROALBUMINURIA; NEPHROTOXICITY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RENAL CLEARANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURFACE AREA; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBULAR NETWORK; ULTRAFILTRATION; URINARY EXCRETION; VASOCONSTRICTION; ANIMAL; DRUG EFFECTS; GENE THERAPY; KIDNEY; PATHOPHYSIOLOGY;

ANIMALS; GENETIC THERAPY; HUMANS; KIDNEY; OLIGONUCLEOTIDES, ANTISENSE;

EID: 84981303338     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0598     Document Type: Review

References (74)

1. Henry SP, RS Geary, R Yu and AA Levin. (2001). Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Investig Drugs 2:1444-1449.
2. Geary RS, T Ushiro-Watanabe, L Truong, SM Freier, EA Lesnik, NB Sioufi, H Sasmor, M Manoharan and AA Levin. (2001). Pharmacokinetic properties of 2′-O-(2- methoxy-ethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 296:890-897.
3. Henry SP, TW Kim, K Kramer-Strickland, TA Zanardi, RA Fey and AA Levin. (2008). Toxicologic properties of 2′-Omethoxyethyl chimeric antisense inhibitors in animals and man. In: Antisense Drug Technologies: Principles, Strategies and Applications, 2nd edn. Crooke ST, ed. CRC Press, Boca Raton, FL, pp 327-363.
4. Berndt WO. (1982) Renal tubular function. In: Nephrotoxicity: Assessment and Pathogenesis. Bach PW, FW Bonner, JW Bridges, EA Lock, eds. Wiley-Hade Ltd., London, pp 54-65.
5. Anders MW. (1980). Metabolism of drugs in the kidney. Kidney Int 18:636-647.
6. Hook JB, KM McCormack and WM Kluwe. (1979). Biochemical mechanisms of nephrotoxicity. In: Review in Biochemical Toxicology, vol 1. Hodgson E, JR Bend, RM Philpot, eds. Elsevier, New York, pp 58-73.
7. Brenner BM, I Ichikawa and WM Deen. (1981). Glomerular filtration. In: The Kidney. Brenner BM, FC Rector, eds. WB Saunders Co., Philadelphia, pp 289-327.
8. Burg MB. (1981). Renal handling of sodium, chloride, water, amino acids and glucose. In: The Kidney. Brenner BM, FC Rector, eds. WB Saunders Co., Philadelphia, pp 328-370.
9. Schnermann J and DZ Levine. (1975). Tubular control of glomerular filtration rate in single nephrons. Can J Physiol Pharmacol 53:325-330.
10. Baylis C. (1980). The mechanism of decline in glomerular filtration rate in gentamicin-induced acute renal failure in the rat. J Antimicrob Chemother 6:381-388.
11. Luft FC, GR Aronoff and AP Evan. (1982). The reninangiotensin system in aminoglycoside-induced acute renal failure. J Pharmacol Exp Ther 220:433-439.
12. Cheville NF. (1983). Cell Pathology, 2nd edn. Iowa State University Press, Ames, IA, pp 559-588.
13. Kanwar YS. (1984). Biophysiology of glomerular filtration and proteinuria. Lab Invest 51:7-21.
14. Porter GA and WM Bennett. (1981). Toxic nephropathies. In: The Kidney. Brenner BM, FC Rector, eds. WB Saunders Co., Philadelphia, pp 2045-2108.
15. Weening JJ, GJ Fleuren and PJ Hoedemaeker. (1978). Demonstration of antinuclear antibodies in mercuric chlorideinduced glomerulopathy in the rat. Lab Invest 39:405-411.
16. Hertz PH, H Yager and JA Richardson. (1972). Probenecidinduced nephrotic syndrome. Arch Pathol 94:241-243.
17. Slauson DO and RM Lewis. (1979). Comparative pathology of glomerulonephritis in animals. Vet Pathol 16:135-164.
18. Rehan A, KJ Johnson and RC Wiggins. (1984). Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest 51:396-403.
19. Kovnat P, E Labovitz and SP Levinson. (1973). Antibiotics and the kidney. Med Clin North Am 57:1045-1063.
20. Bacon PA, CR Tribe and JC MacKenzie. (1976). Penicillamine nephropathy in rheumatoid arthritis. Q J Med 100:661-684.
21. Nagi AH, F Alexander and AZ Barabas. (1971). Gold nephropathy in rats-light and electron microscopic studies. Exp Mol Pathol 15:354-362.
22. Kaissling B and W Kriz. (1979). Structural analysis of the rabbit kidney. Adv Anat Embryo Cell Biol 56:1-123.
23. Tisher CC. (1981). Anatomy of the kidney. In: The Kidney. Brenner BM, FC Rector, eds. WB Saunders Co., Philadelphia, pp 3-75.
24. Bonner FW, PH Bach and M Sobrota. (1982) The biochemistry of the kidney. In: Nephrotoxicity: Assessment and Pathogenesis. Bach PW, FW Bonner, JW Bridges, EA Lock, eds. Wiley-Haden Ltd., London, pp 27-53.
25. Levinsky NG. (1977). Pathophysiology of acute renal failure. N Engl J Med 296:1453-1457.
26. Oken DE. (1976). Local mechanisms in the pathogenesis of acute renal failure. Kidney Int 10:594-596.
27. Stein JH, RV Patak and MD Lifschitz. (1978). Acute renal failue: clinical aspects and pathophysiology. Contrib Nephrol 14:118-141.
28. Ackerman DM and JB Hook. (1984). Biochemical interations and nephrotoxicity. Fund Appl Toxicol 4:300-314.
29. Davis BB, MB Mattamal and TV Zeuser. (1981). Renal metabolism of drugs and xenobiotics. Nephron 27:187-196.
30. Omura T and R Saito. (1964). The carbon monoxidebinding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
31. Fowler BA, GER Hook and GW Lucier. (1977). Tetrachlorodibenzo-p-dioxin induction of renal microsomal enzyme systems: ultrastructural effects on pars recta (Sa) proximal tubular cells of the rat kidney. J Pharmacol Exp Ther 203:712-721.
32. Kaloyanides GJ. (1984). Aminoglycoside-induced functional and biochemical defects in the renal cortex. Fund Appl Toxicol 4:930-948.
33. Klotman PE and WE Yarger. (1983). Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin. Kidney Int 24:634-638.
34. Williams PD, PD Holohan and CR Ross. (1981). Gentamicin nephrotoxicity. II. Possible membrane changes. Toxicol Appl Pharmacol 61:243-251.
35. Kuo CH, K Malta, SD Sleight and JB Hook. (1983). Lipid peroxidation: a possible mechanism of cephaloridineinduced nephrotoxicity. Toxicol Appl Pharmacol 67:78-88.
36. Kuo CH and JB Hook. (1982). Depletion of renal cortical glutathione content and nephrotoxicity of cephaloridine in rabbits, rats and mice. Toxicol Appl Pharmacol 6:292-302.
37. Rush GF, RA Heim, GD Ponsler and JA Engelhardt. (1992). Cephaloridine-induced renal pathological and biochemical changes in female rabbits and isolated proximal tubules in suspension. Toxicol Pathol 20:155-168.
38. Zbinden G. (1969). Experimental renal toxicity. In: The Kidney: Morphology, Biochemistry and Physiology. Rouiller C, AF Muller, eds. Academic Press, New York, pp 401-476.
39. Gillette JR. (1974). A perspective on the role of chemically reactive metabolites of foreign compounds in toxicity. I. Correlation of change in covalent binding of reactive metabolites with change in the incidence and severity of toxicity. Biochem Pharmacol 23:2785-2794.
40. McMurtry RJ, WR Snodgrass and JR Mitchell. (1978). Renal necrosis, glutathione depletion and covalent binding after acetaminophen. Toxicol Appl Pharmacol 46:87-100.
41. Lipsky JJ and PS Leitman. (1982). Aminoglycoside inhibition of renal phosphatidylinositol phospholipase C. J Pharmacol Exp Ther 220:282-292.
42. Feldman S, MY Wang and GJ Kaloyanides. (1982). Aminoglycosides induce a phospholipidosis in the renal cortex of the rat: an early manifestation of nephrotoxicity. J Pharmacol Exp Ther 220:514-520.
43. Riviere JE, EJ Hinsman, GL Coppoc and WW Carlton. (1981). Single dose gentamicin nephrotoxicity in the dog: early functional and ultrastructural changes. Res Commun Chem Pathol Pharmacol 33:403-418.
44. Hostetler KY and LB Hall. (1982). Inhibition of kidney lysosomal phospholipase A and C by aminoglycoside antibiotics: possible mechanism of aminoglycoside toxicity. Proc Natl Acad Sci U S A 79:1663-1667.
45. Silverstein RL, EH Eigenbrodt and JJ McPhaul. (1981). Interstitial nephritis caused by methicillin. Studies in a case complicating staphylococcal sepsis with acute glomerulonephritis. Am J Clin Pathol 76:316-321.
46. Sabatini S. (1984). Pathophysiology of drug-induced papillary necrosis. Fund Appl Toxicol 4:909-921.
47. Carlton WW and JA Engelhardt. (1989). Experimental renal papillary necrosis in the Syrian hamster. Food Chem Toxicol 27:331-340.
48. Reeves WB, RJ Foley and EJ Weinman. (1985). Nephrotoxicity from non-steroidal anti-inflammatory drugs. South Med J 73:318-322.
49. Valtin H. (1977). Structural and functional heterogeniety of mammalian nephrons. Am J Physiol 233:F491-F501.
50. Oberbauer R, GF Schreiner and TW Meyer. (1995). Renal uptake of an 18-mer phosphorothioate oligonucleotide. Kidney Int 48:1226-1232.
51. Rappaport J, B Hanss, JB Kopp, TD Copeland, LA Bruggeman, TM Coffman and PE Klotman (1995). Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy. Kidney Int 47:1462-1469.
52. Sawai K, M Takenori, Y Takakura and M Hashida. (1995). Renal disposition characteristics of oligonucleotides modified at terminal linkages in perfused rat kidney. Antisense Res Dev 5:279-287.
53. Sawai K, RI Mahato, Y Oka, Y Takakura and M Hashida. (1996). Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther 279:284-290.
54. Butler M, K Stecker and CF Bennett. (1997). Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Nucleos Nucleot 16:1761-1764.
55. Monteith DK, RS Geary, JM Leeds, J Johnston, BP Monia and AA Levin. (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol Sci 46:365-375.
56. Henry SP, H Bolte, C Auletta and DJ Kornbrust. (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120:145-155.
57. Monteith DK, MJ Horner, NA Gillett, M Butler, RS Geary, T Burckin, T Ushiro-Watanabe and AA Levin. (1999). Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol 27:307-317.
58. Henry SP, M Johnson, TA Zanardi, R Fey, D Auyeung, PB Lappin and AA Levin. (2012). Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey. Toxicology 301:13-20.
59. Bendele A, J Seely, C Richey, G Sennello G and G Shopp. (1998). Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42:152-157.
60. Conover CD, R Linberg, CW Gilbert, KL Shum and RG Shorr. (1997). Effect of polyethylene glycol conjugated bovine hemoglobin in both top-load and exchange transfusion rat models. Artif Organs 2:1066-1075.
61. Merski JA and MC Meyers. (1985). Light- and electronmicroscopic evaluation of renal tubular cell vacuolation induced by administration of nitrilotriacetate or sucrose. Food Chem Toxicol 23:923-930.
62. Kone BC, LC Racusen, A Whelton and K Solez. (1986). Acute renal failure produced by combining cyclosporine and brief renal ischemia in the Munich Wistar rat. Clin Nephrol 25 (Suppl. 1):S171-S174.
63. Kintzel PE. (2001). Anticancer drug-induced kidney disorders. Drug Saf 24:19-38.
64. El-Badawi MG, MA Abdalla, HM Bahakim and RA Fadel. (1996). Nephrotoxicity of low-dose methotrexate in guinea pigs: an ultrastructural study. Nephron 73:462-466.
65. Guillermina G, TM Adriana and EM Monica. (1989). The implication of renal glutathione levels in mercuric chloride nephrotoxicity. Toxicology 58:187-195.
66. Geary RS, RZ Yu, T Watanabe, SP Henry, GE Hardee, A Chappell, J Matson, H Sasmor, LCummins and AA Levin. (2003). Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 31:1419-1428.
67. Crooke ST, BF Baker, J Kwoh, W Cheng, D Schulz, S Xia, N Salgado, H-H Bui, CE Hart, et al. (2015). Integrated safety assessment of 2nd generation antisense oligonucleotides in nonhuman primates and healthy human volunteers. Submitted for publication.
68. Stanton R, S Sciabola, C Salatto, Y Weng, D Moshinsky, J Little, E Walters, J Kreeger, D DiMattia, et al. (2012). Chemical modification study of antisense gapmers. Nucleic Acid Ther 22:244-359.
69. Frazier KS. (2015). Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol 43:78-89.
70. van Poelgeest EP, RM Swart, MGH Betjes, M Moerland, JJ Weening, Y Tessier, MR Hodges, AA Levin and J Burggraaf. (2013). Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis 62:796-800.
71. Frazier KS, C Sobry, V Derr, MJ Adams, C Den Besten, S De Kimpe, I Francis, TL Gales, R Haworth, et al. (2014). Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol 42:923-935.
72. Goemans NM, M Tulinius, JT van den Akker, BE Burm, PF Ekhart, N Heuvelmans, T Holling, AA Janson, GJ Platenburg, et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364:1513-1522.
73. Voit T, H Topaloglu, V Straub, F Muntoni, N Decononck, G Campion, SJ De Kimpe, M Eagle, M Guglieri, et al. (2014). Safety and efficacy of drisaersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomized, placebo-controlled phase 2 study. Lancet Neurol 13:987-996.
74. Shen L, A Frazer-Abel, PR Reynolds, PC Giclas, A Chappell, MK Pangburn, H Younis and SP Henry. (2014). Mechanistic understanding of the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. J Pharmacol Exp Ther 351:709-717.